Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Evaluating the Efficacy and Safety of Fluticasone Furoate in the Treatment of Asthma in Adults and Adolescents

ClinicalTrials.gov ID: NCT01431950

Public ClinicalTrials.gov record NCT01431950. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 26, 2026, 12:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomised, Double-blind, Multi-centre Study to Evaluate the Efficacy and Safety of Inhaled Fluticasone Furoate in the Treatment of Persistent Asthma in Adults and Adolescents Currently Receiving Mid to High Strength Inhaled Corticosteroids.

Study identification

NCT ID
NCT01431950
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
238 participants

Conditions and interventions

Conditions

Interventions

  • fluticasone furoate Drug
  • albuterol/salbutamol Drug

Drug

Eligibility (public fields only)

Age range
12 Years to 100 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 31, 2011
Primary completion
Sep 30, 2012
Completion
Sep 30, 2012
Last update posted
Jan 8, 2017

2011 – 2012

United States locations

U.S. sites
19
U.S. states
15
U.S. cities
19
Facility City State ZIP Site status
GSK Investigational Site Long Beach California 90808
GSK Investigational Site Newport Beach California 92663
GSK Investigational Site Colorado Springs Colorado 80907
GSK Investigational Site Clearwater Florida 33756
GSK Investigational Site Albany Georgia 31707
GSK Investigational Site Lexington Kentucky 40503
GSK Investigational Site Metairie Louisiana 70006
GSK Investigational Site Sunset Louisiana 70584
GSK Investigational Site Bethesda Maryland 20814
GSK Investigational Site Plymouth Minnesota 55441
GSK Investigational Site Las Vegas Nevada 89119
GSK Investigational Site Brick New Jersey 08724
GSK Investigational Site Utica New York 13502
GSK Investigational Site Canton Ohio 44718
GSK Investigational Site Cincinnati Ohio 45242
GSK Investigational Site Toledo Ohio 43617
GSK Investigational Site Oklahoma City Oklahoma 73103
GSK Investigational Site Orangeburg South Carolina 29118
GSK Investigational Site Corsicana Texas 75110

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 21 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01431950, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 8, 2017 · Synced Jun 26, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01431950 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →